DINAMIQS inaugurates new cGMP viral vector manufacturing facility in Switzerland
The new site enables end-to-end production of viral vector gene therapies
The new site enables end-to-end production of viral vector gene therapies
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
Subscribe To Our Newsletter & Stay Updated